Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)

Phase Distribution

No phase data available

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(2)

Detailed Status

Completed2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%

Trials by Status

completed2100%

Recent Activity

0 active trials
Showing 2 of 2
completed

A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival

NCT01917214
completed

SUTENT® In The First Line Treatment Of Renal Cell Carcinoma

NCT00460798

Clinical Trials (2)

Showing 2 of 2 trials
NCT01917214

A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival

Completed
NCT00460798

SUTENT® In The First Line Treatment Of Renal Cell Carcinoma

Completed

All 2 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
2